BioMark Diagnostics Inc. BMKDF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -81.02% | 46.70% | 21.95% | -16.23% | -2.28% |
| Total Depreciation and Amortization | 82.58% | -60.87% | 61.15% | -13.50% | -54.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.66% | -11.51% | 72.60% | 32.73% | -62.07% |
| Change in Net Operating Assets | -273.68% | -311.11% | 102.31% | -833.96% | 105.10% |
| Cash from Operations | -115.94% | 39.70% | 58.66% | -69.39% | 34.42% |
| Capital Expenditure | -- | 202.69% | -6,930.16% | -350.00% | -100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -18.79% | 1,511.41% | -97.61% | 156.48% | -- |
| Cash from Investing | -67.95% | 276.98% | -155.70% | 155.95% | -194,471.43% |
| Total Debt Issued | 116.03% | -175.73% | 723.96% | 0.00% | 0.00% |
| Total Debt Repaid | 29.98% | -75.41% | -3.66% | 21.96% | -8.62% |
| Issuance of Common Stock | 506.67% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 200.00% | -- | -- | -- |
| Cash from Financing | 104.84% | -241.55% | 1,051.18% | 41.47% | -103.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.49% | 157.13% | -145.32% | 122.55% | -198.39% |